Loading...
Please wait, while we are loading the content...
Similar Documents
The role of gemtuzumab ozogamicin in acute leukaemia therapy.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Tsimberidou, Apostolia-Maria Giles, Francis J. Estey, Elihu O'Brien, Susan M. Keating, Michael J. Kantarjian, Hagop M. |
| Copyright Year | 2006 |
| Abstract | Gemtuzumab ozogamicin (GO) is an immunoconjugate that binds to CD33 on the surface of acute myeloid leukaemia (AML) blasts and, after internalisation, releases a cytotoxic drug, calicheamicin. GO is approved by the US Food and Drug Administration for the treatment of CD33-positive AML at first relapse in patients 60 years and older who are not candidates for other cytotoxic therapy. GO as a single agent has low antileukaemic activity. When given to patients meeting the criteria noted above, it produces a complete response (CR) rate of only 12%, with another 12% achieving CR with inadequate platelet recovery (CRp). The median survival of patients treated with GO monotherapy is 11.2 months. GO therapy at 9 mg/m(2) is complicated with hepatic veno-occlusive disease in 5-10% of patients, particularly prior to or following stem cell transplantation. GO at lower doses combined with chemotherapy as induction or postremission therapy is promising, however, and phase III trials are ongoing. GO is probably most active in acute promyelocytic leukaemia (APL). It is used for induction regimens in high-risk APL and for the elimination of minimal residual APL. Case reports suggest that GO also has activity in CD33-positive acute lymphoblastic leukaemia. In conclusion, single agent GO can induce responses in patients with CD33-positive AML in first recurrence. The future of GO is its use in combination with other cytotoxic agents. Ongoing clinical trials may better define the role of GO combinations, particularly in untreated AML. |
| Starting Page | 398 |
| Ending Page | 409 |
| Page Count | 12 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://williams.medicine.wisc.edu/mylotarg.pdf |
| PubMed reference number | 16412015v1 |
| Volume Number | 132 |
| Issue Number | 4 |
| Journal | British journal of haematology |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Acute Promyelocytic Leukemia Acute leukemia Acute lymphocytic leukemia Cell Transplantation Chemical and Drug Induced Liver Injury Cytotoxic Chemotherapy Cytotoxin Excretory function Gemtuzumab ozogamicin Hematologic Neoplasms Hepatic Veno-Occlusive Disease Immunoconjugates Leukemia, Myelocytic, Acute Liver diseases Milligram per Square Meter Myeloid Leukemia Patients Platelet Count measurement Precursor Cell Lymphoblastic Leukemia Lymphoma Stem cell transplant Stem cells Venoocclusive disease consolidation therapy lymphoblast pediatric acute myeloblastic leukemia |
| Content Type | Text |
| Resource Type | Article |
